Ontuxizumab: Difference between revisions
Appearance
Content deleted Content added
added Category:Experimental cancer drugs using HotCat |
Lncallahan (talk | contribs) m added unii |
||
Line 26: | Line 26: | ||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = 0M2XT000YC |
|||
| PubChem = |
| PubChem = |
||
| DrugBank = |
| DrugBank = |
Revision as of 02:31, 16 April 2017
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric/humanized hybrid (mouse/human) |
Target | TEM1 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6532H10050N1726O2054S44 |
Molar mass | 147.0 kg/mol g·mol−1 |
Ontuxizumab[1] is a monoclonal antibody designed for the treatment of cancer. It binds to endosialin (TEM1 or CD248).[2]
Phase I trials are complete and the drug was granted orphan drug status by the FDA for sarcoma. It is currently in phase II trials for melanoma, colorectal cancer, sarcoma, and lymphoma.[3]
This drug was developed by Morphotek and Ludwig Institute for Cancer Research.[4]
References
- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- ^ Kiyohara, E; Donovan, N; Takeshima, L; Huang, S; Wilmott, J. S.; Scolyer, R. A.; Jones, P; Somers, E. B.; O'Shannessy, D. J.; Hoon, D. S. (2015). "Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications". Cancer Microenvironment. 8 (2): 111–8. doi:10.1007/s12307-015-0168-8. PMC 4542822. PMID 26085332.
- ^ http://adisinsight.springer.com/drugs/800032178
- ^ http://adisinsight.springer.com/drugs/800032178